SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is actively trending as the community focuses on its ultra-low float and significant short interest, fueled by the company's plans to scale its blockchain-based Plastic Cycle Token traceability system. Traders are discussing the strong potential for a short squeeze, drawing comparisons to its own previous parabolic runs and other low-float, high-volatility stocks. The prevailing sentiment is highly bullish, with many anticipating continued upward momentum as short sellers face increasing pressure.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital (APLD) is a top trending stock as investors eagerly await its upcoming earnings report, which is expected to provide critical updates on hyperscaler contracts and the ChronoScale spin-off. The community is buzzing with discussions of a potential short squeeze, fueled by high short interest and recent bullish analyst coverage, as many anticipate strong forward guidance to solidify APLD's position in the rapidly expanding AI infrastructure sector.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending due to a notable, prolonged downtrend, surprising many given the broader market's rally, with community members expressing frustration over consistent red days. Traders are actively debating whether the stock is oversold, presenting a buying opportunity, or if concerns about its AI strategy and the Vision Pro's reception signal further weakness. Recent news of JPMorgan reportedly taking over the Apple Credit Card from Goldman Sachs adds to the conversation amid calls for the company to deliver a significant catalyst.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to its ultra-low float and significant short interest, with community discussion heavily emphasizing its potential for a short squeeze akin to previous explosive moves seen in similar stocks like $SMX. Traders are keenly awaiting upcoming earnings and contract news as potential catalysts, anticipating a breakout above key price levels driven by these strong technical indicators.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd. is currently trending as community chatter suggests a potential short squeeze, fueled by its ultra-low float, extremely high borrow rates, and inclusion on the Reg SHO list. Traders are actively debating its parabolic upside potential, drawing parallels to previous explosive runners despite skepticism surrounding its underlying fundamentals and "China pump" narratives.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant discussion and volatility following a political statement regarding institutional home buying. Despite an initial market overreaction, the community widely views this as a bullish catalyst for Opendoor, asserting that its iBuying model, focused on individual homeownership, benefits from reduced institutional competition. This sentiment, reinforced by the CEO's clarification, is driving discussions of a potential short squeeze and a buying opportunity as the market interprets the news more accurately.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing Co is actively trending following a mix of significant commercial aircraft orders from Alaska Airlines and substantial new defense contracts. This positive news is navigating a polarized investor sentiment, particularly after recent critical remarks from President Trump regarding defense contractors' capital allocation practices. The community is sharply divided between long-term bullish outlooks driven by an extensive backlog and persistent concerns over production challenges and broader sector impacts from political commentary.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending due to recent remarks from President Trump threatening to ban dividends and share buybacks for defense contractors, sparking widespread investor concern and a sell-off across the sector. Community members are actively debating the potential market overreaction, especially as the company recently secured a significant PAC-3 missile production agreement and reported strong quarterly earnings.

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

Erasca (ERAS) is experiencing significant attention due to a recent sympathy rally linked to AbbVie's potential acquisition of Revolution Medicines, fueled by a shared focus on RAS/MAPK pathway inhibition. This upward movement was tempered by news of an underwritten offering, which sparked community debate between investors concerned about dilution and bulls highlighting the strategic in-licensing of new RAS-targeting assets and ongoing clinical trial advancements. Despite polarized sentiment between short sellers and long-term optimists, strong insider buying and a substantial cash runway continue to be key discussion points.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as the company greenlit construction for an Arctic-grade pilot plant and storage facilities in Greenland, accelerating its Tanbreez rare earths project. This development coincides with intensified geopolitical discussions around potential U.S. involvement in Greenland to secure critical mineral resources for national security. The community is actively discussing CRML's strategic importance in diversifying Western rare earth supply chains and notes increasing institutional interest as key drivers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 7% in the pre-market session.Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share (ADS) or ordinary share they own. Meanwhile, each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for every common or preferred share they own. The combined company will advance a fresh portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-biotherapeutics-combine-clywedog-therapeutics-target">said</a>. Four clinical data milestones are expected within 18 months of transaction closing, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BRNS">BRNS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.The combined company will be renamed “Clywedog Therapeutics, Inc.” and is expected to trade on the Nasdaq under the new ticker symbol “CLYD.” Barinthus Bio ADSs will no longer trade on the Nasdaq following the closing of the transaction in the first half of 2026.The combined company will initially focus on advancing its pipeline in Type 1 diabetes, Type 2 diabetes, and celiac disease, Barinthus said. It is expected to have a cash runway into 2027 with additional investments from Clywedog’s existing investors, OrbiMed and Torrey Pines Investment LLC.Upon closing, shareholders of Barinthus Bio are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis.BRNS shares are up by 22% this year and 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.

Equity

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.


Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Barinthus Biotherapeutics Plc. - ADR

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

Current Price	$0.725
Prev Close	$0.7101
Open	$0.7249
Dividend Yield	0.00%
50-Day Moving Average	$0.8427
Beta	0.77
Avg. Volume	78,475.14
PE Ratio	-0.38

52-Week High	$2.92
52-Week Low	$0.64
Market Capitalization	$28.99M
EPS (Annual)	-$1.55
Price to Book	0.34
Revenue Per Employee	$142,621.89
Enterprise Value/EBITDA	N/A

BRNS
Barinthus Biotherapeutics PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BRNS News

BRNSBarinthus Biotherapeutics PLC - ADR